Bio-Techne licenses antibody to Xencor

By The Science Advisory Board staff writers

April 14, 2021 -- Bio-Techne has licensed an antibody to Xencor for therapeutic development.

Bio-Techne gave access to the antibody for use with Xencor's proprietary XmAb protein engineering technology, which aims to develop new cancer therapeutics such as bispecific antibodies and engineered cytokines. This is Bio-Techne's third licensing agreement with Xencor, the firms said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.